Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon

MLA

Jiayi Yu, et al. “Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon.” Translational Oncology, vol. 10, no. 5, Oct. 2017, pp. 719–25. EBSCOhost, https://doi.org/10.1016/j.tranon.2017.06.004.

APA

Jiayi Yu, Xiaowen Wu, Huan Yu, Siming Li, LiLi Mao, Zhihong Chi, Lu Si, Xinan Sheng, Chuanliang Cui, Jie Dai, Meng Ma, Huan Tang, Tianxiao Xu, Junya Yan, Yan Kong, & Jun Guo. (2017). Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon. Translational Oncology, 10(5), 719–725. https://doi.org/10.1016/j.tranon.2017.06.004

Chicago

Jiayi Yu, Xiaowen Wu, Huan Yu, Siming Li, LiLi Mao, Zhihong Chi, Lu Si, et al. 2017. “Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon.” Translational Oncology 10 (5): 719–25. doi:10.1016/j.tranon.2017.06.004.